July 19, 2011 Veterans of J&J, Pfizer, and Medimmune Seek to Transform Arno into Oncology Powerhouse Read More » June 27, 2011 Arno Therapeutics Names Alexander Zukiwski, M.D., Vice President and Chief Medical Officer Read More » May 26, 2011 Tigris Pharmaceuticals Initiates Randomized Phase 2 Study of AFP-464 in ER-Positive Breast Cancer Patients Read More » May 3, 2011 Nile Therapeutics Announces Dosing of First Patient in Phase I Study of Cenderitide Read More » April 28, 2011 Arno Therapeutics Announces the Appointment of Mr. Glenn Mattes as President and Chief Executive Officer Read More » March 31, 2011 Nile Therapeutics Receives Fast Track Designation for Cenderitide for Post-Acute Indication Read More » March 9, 2011 Kite Pharma Raises $15 Million in Initial Round of Financing and Appoints David Bonderman to Board of Directors. Read More » February 28, 2011 Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease Read More » February 28, 2011 Nile Therapeutics Announces Plans to Pursue a Post-Acute Indication in Heart Failure Read More » September 20, 2010 Kite Pharma Appoints Dr. Gloria Lee Chief Medical Officer. Read More » September 16, 2010 Aya Jakobovits, Ph.D., Named President and CEO of Kite Pharma, Inc. Read More » September 13, 2010 Arno Therapeutics, Inc. Raises $15 Million in Private Placement To Advance Clinical Development of Oncology Compounds Read More »

© Two River. All Rights Reserved. Design by Sixty Five Design